April 17, 2019 / 12:38 AM / 5 months ago

BRIEF-Novartis AG Says Avexis Data Reinforce Effectiveness Of Zolgensma In Treating SMA Type 1

April 16 (Reuters) - Novartis AG:

* AVEXIS DATA REINFORCE EFFECTIVENESS OF ZOLGENSMA® IN TREATING SPINAL MUSCULAR ATROPHY (SMA) TYPE 1

* AVEXIS DATA REINFORCE EFFECTIVENESS OF ZOLGENSMA® IN TREATING SPINAL MUSCULAR ATROPHY (SMA) TYPE 1

* INTERIM AVEXIS DATA FROM PHASE 3 STR1VE TRIAL OF ZOLGENSMA IN SPINAL MUSCULAR ATROPHY TYPE 1 SHOWED PROLONGED EVENT-FREE SURVIVAL

* INTERIM DATA FROM PHASE 3 STR1VE TRIAL OF ZOLGENSMA ALSO SHOWED EARLY AND RAPID INCREASE IN CHOP-INTEND SCORES

* INTERIM DATA FROM PHASE 3 STR1VE TRIAL OF ZOLGENSMA ALSO SHOWED SIGNIFICANT MILESTONE ACHIEVEMENT COMPARED TO UNTREATED NATURAL HISTORY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below